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Abstract

(after Cameron & Pauling [2])

Vitamin C (ascorbic acid, ascorbate) has a controversial history in
cancer treatment. Emerging evidence indicates that ascorbate in cancer treatment deserves re-examination. As research results concerning ascorbate pharmacokinetics and its mechanisms of action against
tumor cells have been published, and as evidence from case studies
has continued to mount that ascorbate therapy could be effective if the
right protocols were used, interest among physicians and scientists
has increased.

Other researchers reported benefit consisting of increased survival, improved well-being and reduced pain. However, two randomized clinical trials with oral ascorbate conducted by the Mayo Clinic
showed no benefit. These negative results dampened, but did not permanently extinguish, interest in ascorbate therapy or research. Some
research groups conducted rigorous research, particularly in the area
of administering mega-doses of ascorbate intravenously [3].
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Introduction
Ascorbic acid (vitamin C, ascorbate) has been shown to protect cells
against various types of oxidant injury at physiologically relevant concentrations. Vitamin C has been suggested as having both a preventative and therapeutic role in a number of pathologies when administered at much higher-than-recommended dietary allowance levels.
Despite some initial skepticism on the use and efficacy of high-dose
Vitamin C as anticancer treatment, some recent findings seem to
support such a practice. Here we will survey some recent literatures
around this controversial topic. There is even one book devoted to the
use of Vitamin C for anticancer [1].
Vitamin C (ascorbic acid, ascorbate) has been well documented to
reduce the incidence of most malignancies in humans. What has been
hotly debated is whether vitamin C has any therapeutic effect in the
treatment of cancer. Cameron and Pauling reported in 1976 and 1978
that highdose vitamin C (typically 10 g/day, by intravenous infusion
for about 10 days and orally thereafter) increased the average survival
of advanced cancer patients and for a small group of responders, survival was increased to up to 20 times longer than that of controls [2].
According to Cameron and Pauling, results of the use of Vitamin C to
extend live of patients are encouraging. See table 1 below.
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History
A more complete historical account of Vitamin C can be found in
Gonzalez & Miranda-Massari [1].
Such an early development around 60s and 70s have been supported
by later findings, therefore the use of highdose Vitamin C for anticancer purpose has become more or less accepted. But the remaining
question is: what are the exact mechanism of Vitamin C as anticancer
agent?
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Figure 1: Differences of Average Survival Times of Ascorbate-treated Patients

Pharmacokinetics

Possible Mechanism

According to Mikirova et al.

We shall emphasize here that many mechanisms of action for ascorbate efficacy against cancer have been proposed over the years. Cancer
patients are often deficient in vitamin C, and require large doses to
replenish depleted stores. It has been demonstrated in vitro and in
animal studies that vitamin C is preferentially toxic to tumor cells at
millimolar concentrations; moreover, pharmacokinetic data suggest
that these concentrations are clinically achievable when ascorbate is
administered intravenously. Data suggests that ascorbate may serve as
a biological response modifier, affecting inflammation and angiogenesis as well as improving immune function parameters [4].

“Vitamin C is water-soluble, and is limited in how well it can be absorbed when given orally. While ascorbate tends to accumulate in
adrenal glands, the brain, and in some white blood cell types, plasma levels stay relatively low. According to the study, the plasma levels
in healthy adults stayed below 100 µM, even if 2.5 grams were taken
when administered once daily by the oral route.
Cancer patients tend to be depleted of vitamin C: fourteen out of
twenty-two terminal cancer patients in our phase I study were depleted of vitamin C, with ten of those having zero detectable ascorbate
in their plasma. In a study of cancer patients in hospice care, thirty
percent of the subjects were deficient in vitamin C. Deficiency (below
10 µM) was correlated with elevated inflammation marker C-reactive
protein (CRP) and shorter survival times. Given the role of vitamin
C in collagen production, immune system functioning, and antioxidant protection, it is not surprising that subjects depleted of ascorbate
would fare poorly in mounting defenses against cancer. This also suggests that supplementation to replenish vitamin C stores might serve
as adjunctive therapy for these patients”[4].
While generally speaking, such use of high dose of Vitamin C is considered harmless, there are potential side effects as reported by Unlu
et al. [5].
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More descriptions of mechanism of Vitamin C as anticancer agent can
be found in Gonzalez & Miranda-Massari [1].
Frei and Lawson also add some interesting fact that Vitamin C is able
to kill cancer cells without harming normal cells. They wrote[6]:
“Why is it important to understand how vitamin C can produce H2O2
and kill cancer cells but not normal cells? Because without this detailed knowledge, we do not have a scientific rationale to revisit the
question of whether i.v. infusion of vitamin C may have value in treating cancer patients. The potential cancer-therapeutic activity of vitamin C has a long and controversial history. In 1973, Linus Pauling
and Ewan Cameron postulated that vitamin C inhibits tumor growth
by enhancing immune response and stabilizing glycosaminoglycans
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of the extracellular matrix by inhibiting hyaluronidase. Cameron and
Campbell reported on the response of 50 consecutive patients with
advanced cancer to continuous i.v. infusions (5–45 g/d) and/or oral
doses (5–20 g/d) of vitamin C. No or minimal response was observed
in 27 patients; 19 patients exhibited tumor retardation, cytostasis, or
regression; and 4 patients experienced tumor hemorrhage and necrosis. The first clinical study by Cameron and Paulingcompared survival
times between 100 patients with terminal cancer treated with i.v. and
oral vitamin C, usually 10 g/d, and 1,000 comparable patients not given vitamin C. Patients treated with vitamin C survived approximately
four times longer than controls, with a high degree of statistical significance (P 0.0001). A follow-up study reported that patients given vitamin C had a mean survival time almost 1 year longer than matched
controls. Overall, 22% of vitamin C-treated patients but only 0.4% of
controls survived for more than 1 year.”

Chemotherapy Controversy
With regards to possible interaction with chemotherapy, Mikirova et
al. have reported:
“The observations that ascorbate is an antioxidant and that it preferentially accumulates in tumors have raised fears that ascorbate supplementation would compromise the efficacy of chemotherapy. In
support of this, Heaney and coworkers found that tumor cells in vitro
and xenografts in mice were more resistant to a variety of anticancer agents when the tumor cells were pretreated with dehydroascorbic acid. Questions have been raised, however, whether the experimental conditions used in this study are clinically or biochemically
relevant, considering, among other issues, that dehydroascorbic acid
rather than ascorbic acid was used [7]. A variety of laboratory studies
suggest that, at high concentrations, ascorbate does not interfere with
chemotherapy or irradiation and may enhance efficacy in some situations. This is supported by meta-analyses of clinical studies involving
cancer and vitamins; these studies conclude that antioxidant supplementation does not interfere with the toxicity of chemotherapeutic
regiments” [4].

A Few Recent Reports
There are a number of recent studies which indicate that interest in the
efficacy of ascorbic acid for preventing and cure of tumor and cancer
cells have revived. We will review a few of these recent literatures:
a. Ali Ghanem et al. reported: “The notion of mega doses of ascorbic
acid (vitamin C) for cancer treatment has recently been revived. Besides animal experimentation, evidence from cellular and molecular
research suggests a combined oxidative and metabolic mechanism
behind the specific cytotoxicity of vitamin C towards cancerous cells.
BAOJ Cancer Res Ther, an open access journal
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Here we investigate the efficacy of vitamin C against breast cancer
cell lines. This work showcases a distinctive metabolic shift induced
by ascorbate across multiple cell lines, disruption in the RedOx homeostasis, and the consequent cytotoxic effects. To further deﬁne
the source of ascorbate’stoxicityweprobedthepotentialuptakeroutsofbothascorbicacidand dehydroascorbate (the oxidized form of ascorbic
acid) and the extra and intra cellular ROS resulting from ascorbate
treatment”[8].
b. But what kind of mechanism of anticancer effect of ascorbic? A
number of recent papers try to elucidate these question. In a report,
Birandra K. Sinha et al. suggests that Topotecan may hold an answer.
Their abstract goes as follows: “Topotecan, a derivative of camptothecin, is an important anticancer drug for the treatment of various human cancers in the clinic. While the principal mechanism of tumor
cell killing by topotecan is due to its interactions with topoisomerase I,
other mechanisms, e.g., oxidative stress induced by reactive free radicals, have also been proposed. However, very little is known about how
topotecan induces free radical-dependent oxidative stress in tumor
cells. In this report we describe the formation of a topotecan radical,
catalyzed by a peroxidase-hydrogen peroxide system. While this topotecan radical did not undergo oxidation-reduction with molecular
O2, it rapidly reacted with reducedglutathione and cysteine, regenerating topotecan and forming the corresponding glutathiyl and cysteinyl
radicals. Ascorbic acid, which produces hydrogen peroxide in tumor
cells, signiﬁcantly increased topotecan cytotoxicity in MCF-7 tumor
cells. The presence of ascorbic acid also increased both topoisomerase
Idependent topotecan-induced DNA cleavage complex formation and
topotecan-induced DNA double-strand breaks, suggesting that ascorbic acid participated in enhancing DNA damage induced by topotecan
and that the enhanced DNA damage is responsible for the synergistic
interactions of topotecan and ascorbic acid. Cell death by topotecan
and the combination of topotecan and ascorbic acid was predominantly due to necrosis of MCF-7 breast tumor cells”[9].
C. Jiliang Xia et al. also conclude that pharmacologically-dosed ascorbic acid can help to kill multiple myeloma tumor cells. Their abstract
goes as follows: “High-dose chemotherapiesto treat multiple myeloma (MM) can be life-threatening due to toxicities to normal cells
and there is a need to target only tumor cells and/or lower standard
drug dosage without losing efficacy. We show that pharmacologically-dosed ascorbic acid (PAA), in the presence of iron, leads to the formation of highly reactive oxygen species (ROS) resulting in cell death.
PAAselectively kills CD138+MM tumor cells derived from MM and
smoldering MM (SMM) but not from monoclonal gammopathy undetermined signiﬁcance (MGUS) patients. PAA alone or in combination with melphalan inhibits tumor formation in MM xeno graft mice.
This study shows PAA efficacy on primary cancer cells and cell lines
invitro and invivo”[10].
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d. But there is caveat too, other report shows that pyruvate diminishes
the anticancer effect of ascorbic acid. Their abstract goes as follows:
“The anticancer potential of ascorbic acid (AA) has been controversially discussed for decades. Although the cytotoxic effect of pharmacologic concentrations of ascorbic acid has already been successfully
demonstrated in numerous studies invitro, it could not be veriﬁed to
the same extent invivo. We propose that the ubiquitous metabolite pyruvate diminishes the effect of AA by reacting with its presumable cytotoxic mediator hydrogen peroxide (H2O2). MTT assays conﬁrm that
co-incubation with 1.4 mM pyruvate abolishes the cytotoxic effect
of pharmacologic concentrations of AA in all cancer cell lines tested
(human melanoma (WM451-Lu), breast (MCF-7) and hypopharyngeal cancer cells (FaDu)). We further investigated whether pyruvate
diminishes the anticancer effect of AA by interfering with the generation of (H2O2). Therefore, we analyzed the concentration of AFR, a
proposed intermediate in the AA-dependent formation of H2O2, by
electron paramagnetic resonance spectroscopy, during incubation
with AA and pyruvate in WM451-Lu cells as a model system. In addition, we measured H2O2 concentration by indirect detection with
Clark-type oxygen electrode. AFR concentration was not signiﬁcantly
inﬂuenced by pyruvate, whereas H2O2 concentration was signiﬁcantly
reduced. In parallel, pyruvate concentrations of the stimulation medium declined with increasing AA and consequently H2O2 concentrations. In summary, pyruvate diminishes the cytotoxic activity of ascorbic acid in vitro. The AFR concentration measured remains unaffected
by pyruvate whereas the H2O2 concentration is reduced; conﬁrming
that pyruvate directly reacts with AA-induced H2O2, without inﬂuencing its formation” [11].
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of this simple nutrient”[2].
Nonetheless, this short review is not sufficient, it is recommended to
continue further studies and procedures to maximize such positive
impact of ascorbic acid as anticancer treatment.
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To conclude this short review, allow us to quote Cameron & Pauling:
“There is good evidence that high intakes of ascorbate potentiate the
immune system in various ways: increasing the production and effectiveness of antibodies and crucial components of the complement cascade, enhancing lymphocyte blastogenesis, stimulating macrophage
chemotaxis, improving phagocytic ability, amplifying lymphocyte
trapping, and increasing the proliferation and differentiation of antigen-triggered lymphocytes.
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Ascorbate offers some protection against oncogenic viruses and
against a variety of known chemical and physical carcinogens, and is
also involved in a number of biological processes, discussed in this
review, that are known to contribute to host resistance to neoplastic
disease. There is a growing suspicion that “host resistance to cancer,”
no matter how measured, is largely dependent upon the dietary intake
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